SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

08 Feb 2024 Evaluate
The sales for the December 2023 quarter moved up 38.08% to Rs. 2205.91 millions as compared to Rs. 1597.60 millions during the corresponding quarter last year.The Total revenue for the quarter ended December 2023 of  Rs. 305.45  millions  grew by 354.00% from Rs. 67.28 millions.Operating profit for the quarter ended December 2023 rose to 433.51 millions as compared to 225.89 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 2205.91 1597.60 38.08 6022.66 4559.98 32.08 6658.98 5569.74 19.56
Other Income 74.36 89.31 -16.74 175.04 177.02 -1.12 194.31 90.03 115.83
PBIDT 433.51 225.89 91.91 992.60 616.33 61.05 1030.49 662.62 55.52
Interest 35.37 76.80 -53.95 128.80 247.41 -47.94 322.26 320.12 0.67
PBDT 398.14 149.09 167.05 863.80 368.92 134.14 1100.33 342.50 221.26
Depreciation 92.69 81.81 13.30 248.18 475.74 -47.83 547.86 870.21 -37.04
PBT 305.45 67.28 354.00 615.62 -106.82 -676.32 552.47 -527.71 -204.69
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 305.45 67.28 354.00 615.62 -106.82 -676.32 552.47 -527.71 -204.69
Equity 507.19 408.16 24.26 507.19 408.16 24.26 408.16 408.16 0.00
PBIDTM(%) 19.65 14.14 38.99 16.48 13.52 21.94 15.48 11.90 30.08

Orchid Pharma Share Price

567.50 22.55 (4.14%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×